Neurotransmitter-Dopamine Interactions

*1. Charles D. Blaha Acetylcholine-dopamine interactions Department of Psychology, University of Memphis, Memphis, Tennessee 38152-6400, USA Tel: +1 901 678 1560; fax: +1 901 678 2579; e-mail: cblaha@memphis.edu *2. Vincenzo Di Matteo, SEROTONIN-DOPAMINE INTERACTIONS Istituto di Ricerche Farmacologiche "Mario Negri" Consorzio "Mario Negri" Sud Via Nazionale 8 66030 Santa Maria Imbaro (Chieti) Italy Tel.: +39-872-570366 Fax: +39-872-570416 E-mail: vdimatteo@negrisud.it *3. Michael S. Levine GLUTAMATE-DOPAMINE INTERACTIONS Mental Retardation Research Center, Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA 90095, USA. Telephone, 310-825-7595; fax, 310-206-5060; e-mail, mlevine@mednet.ucla.edu *4. Kjell Fuxe ADENOSINE-DOPAMINE INTERACTIONS Department of Physiology and Pharmacology, Karolinska Institutet, S-171 77 Stockholm, Sweden; e-mail: kjell.fuxe@ki.se *5. George B. Stefano OPIOID-DOPAMINE INTERACTIONS Neuroscience Research Institute, State University of New York-College at Old Westbury, P.O. Box 210, Old Westbury, NY 11568, USA. gstefano@sunynri.org *6. Javier Fernandez-Ruiz CANNABINOIDS-DOPAMINE INTERACTION Departamento de Bioquimica y Biologia Molecular, Facultad de Medicina, Universidad Complutense, 28040-Madrid (Spain) Phone number: 34-913941450; Fax number: 34-913941691 e-mail: jjfr@med.ucm.es or J.Fernandez-Ruiz@ciberned.es *7. Ariel Y. Deutch hypocretin/orexin-DOPAMINE INTERACTIONS Department of Psychiatry, Vanderbilt University Medical Center, Nashville, TN 37212, USA. ariel.deutch@Vanderbilt.Edu) *8. Tracey A. Baskerville oxytocin dopamine Interactions Centre for Integrative Physiology, SBMS, University of Edinburgh, Hugh Robson Building, George Square, Edinburgh, UK Tracey.Baskerville@ed.ac.uk; t.a.baskerville@sms.ed.ac.uk. *9. Giuseppe Di Giovanni nitric oxide-dopamine interection Department of Physiology and Biochemistry, University of Malta, Msida MSD 2080, Malta. giuseppe.digiovanni@um.edu.mt. Cardiff School of Biosciences, Biomedical Building, Museum Avenue, Cardiff CF10 3US, UK. digiovannig@cardfiff.ac.uk *Therese Di Paolo "STEROIDS-DOPAMINE INTERACTIONS" Molecular Endocrinology and Oncology Research Center, Laval University Medical Center, Laurier Blvd. Quebec, G1V 4G2, 2705 Quebec, Canada therese.dipaolo@crchul.ulaval.ca *Marie-Francoise Chesselet GABA-DOPAMINE INTERACTIONS Department of Neurology, David Geffen School of Medicine at UCLA, University of California-Los Angeles, 710 Westwood Plaza, Los Angeles, CA 90064, USA. mchessel@ucla.edu *Pierre Blier NOREPINEPHRINE- DOPAMINE INTERACTIONS MD, PhD University of Ottawa Institute of Mental Health Research Royal Ottawa Hospital Ottawa, Ont. pblier@rohcg.on.ca *Franco J. Vaccarino CHOLECYSTOKININ-DOPAMINE INTERACTIONS Department of Psychology, Sidney Smith Hall University of Toronto 100 St. George Street, Toronto, Ontario, Canada M5S 1A1 Tel: (416) 978-7818 Fax: (416) 978-4811 e-mail: vaccar@psych.utoronto.ca * Ariel Y. Deutch hypocretin/orexin-DOPAMINE INTERACTIONS Department of Psychiatry, Vanderbilt University Medical Center, Nashville, TN 37212, USA. ariel.deutch@Vanderbilt.Edu) 15. Tracey A. Baskerville oxytocin dopamine Interactions Centre for Integrative Physiology, SBMS, University of Edinburgh, Hugh Robson Building, George Square, Edinburgh, UK Tracey.Baskerville@ed.ac.uk; t.a.baskerville@sms.ed.ac.uk.